Search Results

October 2022 Design and validation of recombinant protein standards for quantitative Western blot analysis CB1 receptor C-terminal tail for use as standard and negative control, respectively, in quantitative Western Estimated values of CB1 receptor density obtained by quantitative Western blot were of the same order

October 2022 "Alzheimer's disease (AD) is the most common dementia in the elderly and its increasing Despite a better understanding of the disease, the current mainstay of treatment cannot modify pathogenesis suggests adenosine G protein-coupled receptors (GPCRs) are promising therapeutic targets for Alzheimer's disease In this review, we provide an accessible summary of the literature on Alzheimer's disease and the therapeutic

August 2022 "Alzheimer's disease (AD) is the most common dementia in the elderly and its increasing prevalence Despite a better understanding of the disease, the current mainstay of treatment cannot modify pathogenesis suggests adenosine G protein-coupled receptors (GPCRs) are promising therapeutic targets for Alzheimer's disease In this review, we provide an accessible summary of the literature on Alzheimer's disease and the therapeutic

Concentrations in Portal Venous Blood as a Possible Mechanism for Microbiota Effects on the Immune System, and Western Diseases Published date November 20, 2023 Abstract "We show that the gut bacterial metabolites, short pro-inflammatory immune cells may travel to tissues such as the brain, the lung, the kidney etc and promote disease lifestyle diseases, most of which are immune based, in tissues remote from the gut." Authors Quanbo Wang , Charles R Mackay Tags Gut microbiota , Western lifestyle diseases , portal vein

and Genetic Preclinical Models of Ghrelin Receptor Functional Selectivity to Investigate Metabolic Disease GPCR biased signaling to design/develop new pharmacotherapeutics to treat reward- and metabolism-based diseases reward and its downstream dysregulation of metabolic function, particularly in response to obesogenic 'Western novel GPCR pharmacotherapies that improve efficacy and minimize side effects for diet-induced metabolic diseases

Kevin is also Director, Biomedical Innovation at The University of Western Australia (UWA) and the MTPConnect Western Australian Life Sciences Innovation Hub. Kevin Pfleger on the web LinkedIn ResearchGate Pubmed Google Scholar University of Western Australia